Targeted therapy

April 15, 2022

Now Enrolling: ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as it Continues to Locate Patients with BRAF Mutations

The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.
February 24, 2022

Now Enrolling: EA2205 for a Rare Form of Liver Cancer

ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma
January 26, 2022

Now Enrolling: EA3202 for Head and Neck Squamous Cell Carcinoma

This phase II/III study is exploring new treatment approaches for patients with recurrent and metastatic head and neck squamous cell carcinoma
December 22, 2021

Trial Spotlight: Helena Yu on the EA5182 Trial for Metastatic, EGFR-Mutant Non-Small Cell Lung Cancer

This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy
November 16, 2021

Trial Results: ASCO Highlights Practice-Changing Results in Melanoma

The phase III DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
September 30, 2021

Now Enrolling: Phase II of EA9152 for Acute Lymphoblastic Leukemia

This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL
May 28, 2021

Now Enrolling: EA2192/APOLLO for Pancreatic Cancer

This phase II study, led by Dr. Kim Reiss Binder, is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
March 31, 2021

Now Enrolling: EA6194 for Operable Melanoma

This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
January 14, 2020

Institution Spotlight: Fox Chase Cancer Center

A Standing Main Member of ECOG-ACRIN since 1971